What makes ependymoma in infants different?
Looking at molecular makeup and MRIs to characterise infant ependymoma.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Looking at molecular makeup and MRIs to characterise infant ependymoma.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Looking into whether survivors of childhood cancer are at risk of severe infections.
Developing better models of rhabdomyosarcoma to test available treatments.